APA (7th ed.) Citation

KE, S., CA, P., C, Y., ST, K., T, G., MD, M., . . . CF, K. (2025). Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): A first-in-human, phase 1 randomised trial. The lancet. HIV, 12(6), e405. https://doi.org/10.1016/S2352-3018(25)00012-8

Chicago Style (17th ed.) Citation

KE, Seaton, et al. "Safety, Pharmacokinetics, and Neutralisation Activity of PGDM1400LS, a V2 Specific HIV-1 Broadly Neutralising Antibody, Infused Intravenously or Subcutaneously in People Without HIV-1 in the USA (HVTN 140/HPTN 101 Part A): A First-in-human, Phase 1 Randomised Trial." The Lancet. HIV 12, no. 6 (2025): e405. https://doi.org/10.1016/S2352-3018(25)00012-8.

MLA (9th ed.) Citation

KE, Seaton, et al. "Safety, Pharmacokinetics, and Neutralisation Activity of PGDM1400LS, a V2 Specific HIV-1 Broadly Neutralising Antibody, Infused Intravenously or Subcutaneously in People Without HIV-1 in the USA (HVTN 140/HPTN 101 Part A): A First-in-human, Phase 1 Randomised Trial." The Lancet. HIV, vol. 12, no. 6, 2025, p. e405, https://doi.org/10.1016/S2352-3018(25)00012-8.